Skip to main content
. 2019 Nov 25;20(23):5914. doi: 10.3390/ijms20235914

Figure 2.

Figure 2

Emetine synergizes with cisplatin to enhance its anticancer efficacy in human NSCLC cells. Cell lines were exposed to a constant-ratio combination of emetine and cisplatin for 48 hours. Cell viability was measured using an MTS assay. The synergism of emetine and cisplatin was assessed by constructing isobolograms and calculating combination index (CI) values using the Chou-Talalay method in CompuSyn software (ComboSyn, Inc.). (A) A549, (B) CL1-0, (C) CL1-5, (D) H1299, (E) H1355, (F) H1437, (G) H358, (H) H647. For each cell line, the isobologram (left) shows the drug combination at the ED50, ED75 and ED90 effect levels. The Fa-CI plot (right) shows the combination index as a function of the fraction affected. Synergistic effects are indicated by values below the line in the isobologram or as a CI of < 1 in the Fa-CI plot; additive effects are indicated by values close to the line in the isobologram or as a CI of 1, and antagonistic effects are indicated by values above the line in the isobologram or as a CI of >1. The data are representative of three independent experiments performed in triplicate. ED50, 50% effective dose. ED75, 75% effective dose. ED90, 90% effective dose.